^
Association details:
| Biomarker: | CRLF2 overexpression |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) + Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-term outcomes of newly diagnosed CRLF2 rearranged B-cell ALL.
Published date:
05/26/2022
Excerpt:
Among the HCVAD/mini-HCVD treated pts, 37% received blina in CR1 during consolidation at a median of 3.6 months after starting induction therapy, 34% received ino in CR1 (most commonly starting in cycle 1 as part of mini-HCVD + ino regimen) and 22% received both ino and blina in CR1...The median RFS and OS was 17.6 and 26.6 mos, respectively. CR/CRp rate after C1 among pts who received mini-HCVD + ino in C1 was 100% (14/14) with 79% MRD-neg. On landmark analysis to the time to blina initiation, blina treated pts had similar RFS and trended for improved OS...
Secondary therapy:
CVAD
DOI:
10.1200/JCO.2022.40.16_suppl.7040
Source:
Title:
LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/12/2022
Excerpt:
To study the outcomes of newly diagnosed CRLF2 rearranged B-ALL treated with hyper CVAD based regimens and the impact of targeted therapies like inotuzumab and blinatumomab. All pts had overexpression of CRLF2...Among the 32 pts who received ino and/or blina, the median RFS and OS was 17.6 mos and 38.8 mos respectively.
Secondary therapy:
CVAD
